These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3093154)

  • 21. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli.
    Sader HS; Huynh HK; Jones RN
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):547-50. PubMed ID: 14596974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro activity of pefloxacin against micro-organisms multiply resistant to beta-lactam antibiotics and aminoglycosides.
    Verbist L
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():11-7. PubMed ID: 3086278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fluoroquinolone and aminoglycoside resistance in chromosomal cephalosporinase-overproducing gram-negative bacilli strains with inducible beta-lactamase].
    López-Yeste M; Xercavins M; Lite J; Cuchí E; Garau J
    Enferm Infecc Microbiol Clin; 1996 Apr; 14(4):211-4. PubMed ID: 9044634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ciprofloxacin in combination with other antimicrobials.
    Eliopoulos GM; Eliopoulos CT
    Am J Med; 1989 Nov; 87(5A):17S-22S. PubMed ID: 2511757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620 compared to that of other antimicrobial agents.
    Hirschhorn L; Neu HC
    Chemotherapy; 1987; 33(1):28-39. PubMed ID: 3549179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of A-56619 and A-56620 against multi-resistant and routine clinical isolates.
    Fernandes CJ; Wilson RD; Ackerman VP
    Chemotherapy; 1988; 34(3):216-28. PubMed ID: 3416660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibacterial activity of the new quinolone CI-960 (PD 127391) against clinical isolates at a major tertiary care center in Saudi Arabia.
    Qadri SM; Abo-Askar H; Ueno Y
    Chemotherapy; 1992; 38(2):92-8. PubMed ID: 1317281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of aztreonam, cefotaxime, ceftazidime and imipenem combined with ciprofloxacin against gram-negative bacilli and compared with amikacin combinations against Pseudomonas aeruginosa.
    Díez Enciso M
    Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):90-2. PubMed ID: 1907544
    [No Abstract]   [Full Text] [Related]  

  • 29. In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
    Eliopoulos GM; Moellering AE; Reiszner E; Moellering RC
    Antimicrob Agents Chemother; 1985 Oct; 28(4):514-20. PubMed ID: 3935046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bactericidal activity of imipenem].
    Thabaut A; Meyran M
    Presse Med; 1990 Apr; 19(13):592-7. PubMed ID: 2139938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amifloxacin activity against well-defined gentamicin-resistant, gram-negative bacteria.
    John JF; Twitty JA
    Antimicrob Agents Chemother; 1984 Nov; 26(5):781-4. PubMed ID: 6440481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials.
    Qadri SM; Lee GC; Ellis ME
    Chemotherapy; 1991; 37(3):166-74. PubMed ID: 1889304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro antibacterial activity and clinical significance of domestic fluoroquinolones combinations with other antimicrobial agents].
    Li LJ; Guan L; Wei DJ
    Zhonghua Nei Ke Za Zhi; 1993 Mar; 32(3):148-51. PubMed ID: 8222975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim.
    Digranes A; Dibb WL; Benonisen E
    Chemotherapy; 1985; 31(6):466-71. PubMed ID: 2934234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test.
    Sobottka I; Neumann S; Laufs R
    Chemotherapy; 1994; 40(5):293-8. PubMed ID: 7956451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kucukercan M; Ceran N
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics.
    Wise R; Andrews JM; Patel N
    J Antimicrob Chemother; 1981 May; 7(5):521-9. PubMed ID: 6790507
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.